CURRICULUM VITAE

Nishant Kumar Mishra, FRCP, PhD, FAHA, FESO, MBBS (MD (Conf.))

Contact Information:

Address	100 York Street Ste Suite 1-N New Haven, CT 06511
Email:	nishant.mishra@yale.edu; Nishant.mishra@va.gov;
WebPage	https://medicine.yale.edu/profile/nishant-mishra/
Citizenship	USA (also Overseas Citizen of India)

Statement of Research, Leadership, and International Standing

Overview

For over 20 years, my career has been defined by a commitment to transforming the management of stroke and its long-term complications. My trajectory represents a transition from a skilled clinician identifying complex neurological syndromes to an internationally recognized architect of global research infrastructure. Today, my work at the intersection of **Big Data, genomics, and clinical policy** directly shapes the international standards of care for stroke and post-stroke epilepsy.

Clinical Foundation and Practice-Changing Research (2005–2015)

My early career was dedicated to expanding the boundaries of acute stroke treatment. Through landmark first-author publications in **The BMJ** (Item 13, see below, in Bibliography) and **Stroke** (Items 10, 11, 12), I led the pivotal studies that proved the safety and efficacy of thrombolysis in traditionally "excluded" populations, most notably the very elderly and those with prior stroke and diabetes. This body of work provided the definitive evidence base for the **AHA/ASA, Japanese, and European clinical guidelines**, effectively expanding life-saving treatment eligibility to millions of high-risk patients worldwide.

Global Leadership and Infrastructure Building (2016–Present)

Recognizing that the next frontier of stroke care lies in long-term outcomes, I founded the **International Post Stroke Epilepsy Research Consortium (IPSERC)**. As the senior architect of the **IPSERR repository** (Item 50), I currently work on the disparate clinical datasets from across the globe into the world's most powerful Individual Patient Data (IPD) meta-analysis platform. This leadership has culminated in "gold-standard" evidence published in **JAMA Neurology** (Item 49) and **Neurology** (Item 57), defining the clinical trajectory and pharmacological management of post-stroke seizures for the modern era.

Innovation in Precision Medicine and Federal Impact

My current research program is pioneering the use of **genomic risk stratification** to predict post-stroke complications. By successfully leveraging the **Million Veteran Program (MVP)** data, I have secured **federal VA funding** (co-investigator; Item 55) to develop polygenic risk scores that will allow for personalized, "upstream" prevention of epilepsy. This work, combined with my research on social determinants of health (Item 60), ensures that my scientific contributions remain rooted in health equity and the specific needs of the veteran population.

Mentorship and the Future of the Field

As a faculty member at Yale and with past experience from multiple top world centres, I view my most enduring impact as the success of my trainees. My research team consistently produces high-impact scholarship (Items 49, 51, 55, 57), where I serve as senior mentor to the next generation of academic neurologists. By providing these mentees with a seat at the table of international consortia, I am ensuring a sustainable legacy of scientific excellence and global collaboration.

Conclusion

From my early advocacy for comprehensive stroke programs to my current role leading global data repositories, my career has been dedicated to one goal: improving the lives of stroke survivors through rigorous science and global leadership. I am honored to submit this record as evidence of my sustained contribution to the university, the veteran community, and the international medical field. This is despite several personal losses and hardships along my journey, which have only strengthened my resilience.

Scan-Ready Impact Highlights

- **Journal Track Record:** Lead or Senior author in **The BMJ**, **JAMA Neurology**, **Stroke**, and **Neurology**.
- **Policy Influence:** Research directly cited in **10+ International Clinical Guidelines**(AHA/ASA, UK, Japan, China, Spain, Poland).
- **Federal Funding:** Principal Investigator/Co-Investigator on **VA-funded initiatives**using Big Data (MVP).
- **Global Architecture:** Founder of **IPSERC** and **IPSERR**, platforms utilized by researchers worldwide.

Education: Summary Statement

My academic journey represents a deliberate and rigorous path toward global leadership in stroke neurology. From my PhD at the University of Glasgow to my advanced fellowships at Stanford and UCLA, I have been mentored by the architects of modern stroke therapy. This foundation enabled me to succeed as a clinical neuroscientist across various jurisdictions, secure funding as a co-investigator on a VA project, and lead projects, working closely with the who's who in the fields of stroke and epileptology. I submitted two R01S on arrival at Yale, and resubmissions are pending. As Stroke Director for

the West Haven VA, I bridge the gap between high-level clinical administration and transformative research, ensuring that Yale's scientific breakthroughs are directly translated into veteran care.

Education:

07/1999 - 01/2005	MBBS, Maharashtra University of Health Sciences, Nashik, India, Nashik, MH, India (09/2020: MD, The University of The State of New York, By Conferral, New York)
10/2008 - 04/2012	PhD, University of Glasgow, Acute Stroke Unit, Medicine and Therapeutics, Western Infirmary Hospital, Glasgow, Scotland, United Kingdom

Career/Academic Appointments:

11/2003 - 01/2005	Intern, Medicine, Surgery, and allied, SBH GMC and Grant Medical College and Sir JJ Group of Hospitals, Mumbai (Maharashtra University of Health Sciences, MH, India)
02/2005 - 07/2005	Physician (Houseman/Neurology), Internal Medicine, Division of Clinical Neuroscience, Lilavati Hospital and Research Center (**Mentors**: SM Hastak; PM Dalal), Mumbai, MH, India
08/2005 - 01/2006	Clinical Research Officer, WHO/ STROKE STEPPS - Clinical Stroke Research Program (**PI:** Dr Praful M Dalal), Acute Stroke Unit, Lilavati Hospital and Research Center, Mumbai, MH, India
02/2006 - 06/2006	Project Assistant, Memory and Learning Lab (Basic Sciences; Investigation of the MAP Kinase pathway in memory consolidation; **PI:** Shiv Kumar Sharma, PhD), National Brain Research Center, Delhi, DL, India
10/2006 - 06/2008	Swiss Government's Excellence (ESKAS) Fellow, Clinical Neurology: Stroke and Behavioral Neurology, University Hospital of Lausanne, Unisanté, Lausanne, VD, Switzerland. 20% stroke clinic, 20% behavioral neurology, 60% clinical stroke research (neglect syndrome, aphasia, blindsight)
12/2009	Visiting ESO researcher, Safe Implementation of Treatments in Stroke SITS-ISTR, Neurology, Karolinska University (Collaborator: N. Wahlgren, MD), Stockholm, Stockholm County, Sweden
04/2011	Visiting PhD Researcher, Neurology, UT Houston (Mentors: J. Grotta, MD; Collaborator: TA Kent, MD; P Mandava, MD), Houston, TX
05/2012 - 08/2014	Postdoctoral Fellowship (Stroke Neurology- Clinical Research; PGY 6-7), Neurology, Stanford University, CA; Mentors: G. Albers, MD; M. Lansberg, MD;
06/2015 - 05/2016	ORISE/ OWH Medical Scientist, Centre for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD
06/2016 - 06/2017	Internship, Internal Medicine (PGY1), Tulane University, New Orleans, LA
07/2017 - 06/2018	Neurology Resident, Neurology (PGY2), Tulane University, New Orleans, LA
07/2018 - 06/2020	Neurology Resident, Neurology, Mt. Sinai Hospital, Icahn School of Medicine at Mt. Sinai, New York, NY
07/2018 - 06/2020	Residency, Neurology (PGY3-4), Icahn School of Medicine at Mount Sinai Hospital
07/2020 - 06/2021	Vascular Neurology ACGME Fellow (PGY 5), University of California, Los Angeles NIH StrokeNet Fellow, Neurology, UCLA (Mentors: J. Saver, MD; D.S. Liebeskind, MD), Los Angeles, CA
07/2021 - present	Assistant Professor, Neurology (Department), Yale School of Medicine, New Haven, CT
02/2024 - Present	Stroke Director, Neurology, Veteran Affairs, Connecticut, West Haven, CT

Administrative Positions:

2022 - Present	Affiliated Faculty, Yale Institute of Global Health, Yale University, New Haven, CT
2024 - Present	Stroke Director, U.S. Department of Veterans Affairs, West Haven VA Medical Center, West Haven, CT

Professional Honors & Recognition:

International/National/Regional

2002	Ratan Tata Trust Merit Scholarship, Ratan Tata Trust, Government Medical College
2006-2008	Fellowship in Clinical Neurology (Stroke and Behavioural Neurology), Swiss Government (ESKAS/ FCS award); Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne
2008-2012	Stipend award, University of Glasgow PhD Studentship, University of Glasgow
2008-2011	Tuition award, University of Glasgow studentship, University of Glasgow
2009	Roberts Travel Award, University of Glasgow
2009-2011	Overseas Research Studentship Award (ORSAS), University of Glasgow, Scotland, UK, UK Secretary of State for Education and Science (ORSAS)
2010	Department-to-Department SITS-ISTR collaboration award, Karolinska University, Sweden, European Stroke Organisation
2011	Jim Gatheral Scholarship, UT Houston (Mentor: Dr J. Grotta), University of Glasgow, Scotland
2015-2016	ORISE award, OWH/ US FDA/ Oak Ridge Institute for Science and Education
2017	Exceptional Reviewer, Annals of Internal Medicine
2019	Exceptional Reviewer, Annals of Internal Medicine
2020	R25 NIH award, National Institutes of Health
2020	Leon Levy Foundation award, Leon Levy Foundation
2020	StrokeNet Fellow, 2020-2021, NIH/ UCLA
2023	Fellow of the Royal College of Physicians (FRCP), Royal College of Physician, UK
2025	Polygenic Risk Scores (PRS) to Predict Post-Stroke Epilepsy (PSE) in the Million Veteran Program (MVP) Cohort,
2026	Swellbius Award , Swellbius Foundation 2026-2027

Grants/Clinical Trials History:

Current Grants

Agency:	Department of Veteran Affairs, US Government
I.D.#:	Project Number: MVP107; I21RX005453-01
Title:	Polygenic Risk Scores (PRS) to Predict Post-Stroke Epilepsy (PSE) in the Million Veteran Program (MVP) VA Rehabilitation Research & Development (RR&D) Small Projects in Research (SPiRE) award. Role: Co-Investigator; Local SI.
P.I.:	Marissa Kellogg
Role:	Co-Principal Investigator
Percent effort:	2.5%
Total costs:	$230,000.00
Project period:	04/01/2025 - 03/31/2027

Agency:	Department of Veteran Affairs, US Government
I.D.#:	Project Number: 1853476-4
Title:	Prism Adaptation Therapy (PAT) for Right Brain Stroke Rehabilitation
P.I.:	Anna M Barrett
Role:	Site Investigator
Percent effort:	2.5%
Total costs:	-

Project period:	04/01/2025 - 03/31/2027
Agency:	Swebilius Award
I.D.#:	-
Title:	Swebilius Award: "Harnessing Machine Learning for Deep Patient Phenotyping within the International Post-Stroke Epilepsy Research Repository (IPSERR)"
P.I.:	Nishant Mishra
Role:	Principal Investigator
Percent effort:	N/A
Total costs:	$10,000.00
Project period:	01/01/2026 - 12/31/2026

Invited Speaking Engagements, Presentations & Workshops Not Affiliated With Yale:

International/National

1. "Mismatch-based delayed thrombolysis". Grant Medical College and Sir JJ Group of Hospitals, Mumbai, Invited Talk, Grant Medical College, Mumbai. Chaired by Dr Satish V Khadilkar, Mumbai, MH, January 2010. (Lecture)
2. "Perfusion Imaging to select stroke patients for recanalization therapy". Mumbai Stroke Society, Mumbai Stroke Society Meeting, Chaired by Dr. Bhim Singhal., Mumbai, MH, March 2013. (Lecture)
3. "Use of iv alteplase beyond guidelines". Mumbai Stroke Society; Chaired by Dr Shirish M Hastak, Use of IV alteplase beyond guidelines, Mumbai, MH, March 2015. (Lecture)
4. "Stroke management during the COVID pandemic: An International Perspective". Indian Stroke Association/ Mumbai Stroke Society, Stroke management during the COVID pandemic: An International Perspective, May 1, 2020 | Virtual/International | "Stroke Management During the COVID-19 Pandemic: An International Perspective" | Indian Stroke Association (ISA) Webinar Series Chairs: Dr. Shirish Hastak and Dr. Subhash Kaul, May 2020. (Lecture)
5. "Update on Contemporary Stroke Practice". Connecticut Association of Physicians of Indian Origin, Stratford, CT, CAPI - Journal Club, Invited talk to the CAPI., April 2022. (Lecture)
6. "Prevention of Post-Stroke Epileptogenesis". UCLA, Frontiers in Neurology (UCLA), University of California, Los Angeles, March 2023. (Lecture)
7. "Prevention of Post-Stroke Epilepsy". Icahn School of Medicine at Mt. Sinai, Invited Talk, Icahn School of Medicine at Mt. Sinai, New York, New York, NY, March 2024. (Lecture)
8. "Post-Stroke Epilepsy". American Indian Neurologist Association, Los Angeles, CA, December 2024. (Lecture)
9. "Polygenic risk of poststroke epilepsy". STESS Organisers, Structural Epilepsy & Symptomatic Seizures (STESS/ ILAE). Gothenburg, Gothenburg, O, April 2025. (Lecture)
10. "Post-Stroke Epilepsy". Indian Academy of Neurology Annual Conference 2025, Varanasi, UP, November 2025 - December 2025. (Lecture)
11. "Post-stroke Epilepsy Outcome". American Epilepsy Society, American Epilepsy Society 2025American Epilepsy Society, 2025; Session: SIG | Seizure and Cerebrovascular Disease: Post-stroke Epilepsy Across the Spectrum of Life – From Conception to Death, Atlanta, GA, December 2025. (Address)
12. "Post-Stroke Epilepsy: Research Advances". AINA Research Exchange, The event features distinguished neurology faculties, each presenting their ongoing research for 30 minutes, followed by 10 minutes for Q&A. The goal of the research exchange is to foster collaboration between AINA members, generate new ideas and to facilitate new research grants, publications and knowledge. Speakers: Nishant K. Mishra, MD, PhD, FRCP, FESO, FAHA. and Jaideep Kapur, MBBS, PhD, Charlottesville, VA (Title: Seizures as brain explorers) , March 2026. (Lecture)

Regional

1. "Prevention of Post-Stroke Epileptogenesis". Frontiers in Stroke Science, UCLA, UCLA - invited talk. March 2023. (Lecture)

Peer-Reviewed Presentations Given at Meetings Not Affiliated With Yale:

International/National

1. Outcomes After Thrombolysis Amongst Patients Aged greater than/=80 Years and Patients Having Diabetes or Previous Stroke: A Synopsis (Plenary Session). University of Glasgow, UK, European Stroke Conference (Plenary Session), Barcelona, CT, May 2010. (Lecture)

Professional Service:

Peer Review Groups/Grant Study Sections

2022	External Examiner of PhD Thesis, All India Institute of Medical Sciences, New Delhi, India, External examiner of a Ph.D. in Neurology thesis; Ref: AIIMS/ExamSec/Ph.D/12-04/2022
2023 -	Grant Reviewer, United Kingdom Research and Innovation (UKRI) Medical Research Council (MRC), Invited Grant Reviewer, Medical Research Council (MRC) | UK Research and Innovation (UKRI), United Kingdom. My reputation as an international authority in cerebrovascular disease is further evidenced by my service as a Grant Reviewer for the UKRI Medical Research Council (MRC). By evaluating high-stakes research proposals for the United Kingdom's leading medical research funder, I play a critical role in shaping the global trajectory of stroke and epilepsy scholarship.
2024	Grant Reviewer, National Institutes of Health, Ad hoc reviewer for R01 grant applications within the Brain Injury and Neurovascular Pathologies (BINP) study section. In 2024, I was selected for the NIH Early Career Reviewer (ECR) program, where I served as an ad hoc reviewer for R01 grant applications. This invitation to evaluate the nation's highest-level research proposals at the Center for Scientific Review (CSR) underscores my standing as an expert in the field of stroke and cerebrovascular science.
2025	Grant Reviewer, Swiss National Science Foundation, Expert reviewer for European research proposals focused on post-stroke epilepsy and cerebrovascular outcomes. My international standing in the field of post-stroke epilepsy is evidenced by my invitation to serve as a Grant Reviewer for the Swiss National Science Foundation (SNSF). In this capacity, I provided expert evaluation for European-based clinical research proposals, ensuring the scientific rigour of international efforts to improve outcomes in epilepsy following cerebrovascular injury

Journal Services

Editorial boards

2017 - Present	Editor, Frontiers Neurology, Launched the following two research topics in my area of scientific interests: (1) Reperfusion Therapy for Acute Ischemic Stroke (2017-2019; Co-editor: Bruce Campbell) (2) Intracranial Bleeding After Reperfusion Therapy in Acute Ischemic Stroke (2020-2021; Co-editors: Richard Leigh and Bruce Campbell).
2019 - Present	Associate Editor, Frontiers in Neurology (Stroke), Associate Editor (2019- present)
2021 - Present	Editor, PLOS One, Academic Editor
2022 - Present	Editorial Board Member, Neurology (Green Journal)

Reviewer

2006 - Present	Reviewer, Stroke Journal, Ad-hoc reviewer
2010 - Present	Reviewer, Neurology Journal, Editorial Board Member (2021-present) Ad-hoc reviewer (2006-2021)
2011 - Present	Reviewer, European Journal of Neurology
2011 - Present	Reviewer, Brain, Ad-Hoc reviewer
2012 - Present	Reviewer, Neurocase
2012	Reviewer, ADIS Drug Evaluation, Alteplase: A review of its use in the management of Acute Ischemic Stroke. Co-reviewers: HP Adam, D Leys, S Lorenzano, and D Toni.
2013 - Present	Reviewer, Annals Internal Medicine
2013 - Present	Reviewer, Diabetes Care
2013 - Present	Reviewer, CMAJ
2013 - Present	Reviewer, Frontiers Neurology, Associate Editor since 2019
2016 - Present	Reviewer, BMJ
2017 - Present	Reviewer, Stroke Journal, Recognized by the Editor, Dr. Marc fisher
2020 - Present	Reviewer, Journal of Cerebral Blood Flow and Metabolism, Ad-Hoc Reviewer
2021 - Present	Reviewer, Epilepsy and Behavior
2022 - Present	Reviewer, Clinical Neurology and Neurosurgery
2022 - Present	Reviewer, Alzheimers Disease and Associated Disorders
2022 - Present	Reviewer, BMJ Surgery, Interventions, and Health Technologies
2024 - Present	Reviewer, JNNP - Invited Commentary, Invited Editorial: Mishra NK. Implications for driving based on the risk of seizures after ischaemic stroke. Journal of Neurology, Neurosurgery, and Psychiatry. 2024;95:794.

Professional Organizations

American Epilepsy Society

2021 - Present	Member, American Epilepsy Society

American Heart Association

2022 - Present	Fellow, American Heart Association, FAHA

American Indian Neurologist Association

2023 - Present	Executive Committee Member, American Indian Neurologist Association, Executive Committee Member; https://www.4aina.com/Board

Association of Indian Neurologist Association

2022 - Present	Member, Association of Indian Neurologist Association

European Stroke Organisation

2012 - Present	Fellow, European Stroke Organisation, Fellow of European Stroke Organization (FESO)

European Stroke Organization

2024 - Present	Co-Chair, European Stroke Organization, Guideline development committee

Indian Stroke Association

2020 - Present Member, Indian Stroke Association

World Stroke Organisation

2006 - Present Member, World Stroke Organisation

Yale University / Hospital System

University

2021 - Present Founding Member, International Post-Stroke Epilepsy Research Consortium (IPSERC), Convenor, IPSERC.

Department

2021 - Present Member, Yale Vascular Neurology Fellowship Recruitment Committee

2025 - Present Grant Reviewer, YIGH Faculty Academic Review Committee, I contribute to advancing Yale's research mission, e.g., through my service on the Yale Institute for Global Health (YIGH) Faculty Academic Review Committee. In this capacity, I evaluate grant proposals for scientific rigour and potential impact, applying my expertise in neurology and clinical research to support the university's global health scholarship

Public Service / Media Presence

2025 **Implications for driving based on the risk of seizures after ischaemic stroke**
https://www.medscape.com/viewarticle/model-helps-guide-poststroke-seizure-risk-and-driving-2024a10009ug
Invited Commentary, Invited Editorial*: Mishra NK. Implications for driving based on the risk of seizures after ischaemic stroke. Journal of Neurology, Neurosurgery, and Psychiatry. 2024;95:794*.
My leadership in cerebrovascular disease is recognised by leading academic journals, media, published commentaries, and guideline statements; most recently, the editors of the Journal of Neurology, Neurosurgery, and Psychiatry (JNNP) invited me to author an editorial on the topic. This invitation to provide expert synthesis for a leading international neurology journal underscores my reputation as a specialist who can shape clinical and scientific discourse. I am an internationally recognised expert whose clinical insights are featured in major medical news outlets, including Medscape.

2025 **Video: Post-Stroke Epilepsy — AES 2025 Expert Insights |**
https://www.neurologyadvisor.com/reports/video-post-stroke-epilepsy-aes-2025-expert-insights/

2025 **Improving Quality of Life After a Stroke** https://medicine.yale.edu/news/yale-medicine-magazine/article/improving-quality-of-life-after-a-stroke/ **Summary:** Yale Medicine Magazine highlights efforts to shift stroke care toward long-term neurological health by focusing on the detection and treatment of post-stroke epilepsy, identifying levetiracetam and lamotrigine as highly effective options. The research emphasises intervening within the first few months post-stroke to prevent epileptogenesis, aiming to improve patients' quality of life through tailored, culturally relevant care. Read the full story at Yale Medicine Magazine.

2025 **Post-Stroke Epilepsy: Antihypertensive Choice Could Matter**

https://www.medcentral.com/neurology/post-stroke-epilepsy-antihypertensive-choice-could-matter **Summary**: Research presented at the American Epilepsy Society indicates that angiotensin receptor blockers (ARBs) may reduce the risk of post-stroke epilepsy (PSE) in hypertensive patients compared to other antihypertensives, according to a report from MedCentral. Experts, including Dr Nishant Mishra of Yale University, suggest that these findings support the use of ARBs as a proactive strategy, though further randomised controlled trials are needed to confirm the results. For more details, visit MedCentral

2024 **2024 | Expert Commentator, Medscape Medical News | "Model Guides Poststroke Seizure Risk and Driving Decisions"** | Discussion of JNNP editorial regarding SeLECT 2.0 scoring, COSY risk factors, and driving safety protocols. Model Helps Guide Poststroke Seizure Risk and Driving Decisions. https://www.medscape.com/viewarticle/model-helps-guide-poststroke-seizure-risk-and-driving-2024a10009ug **Summary: Clinical Leadership.** I was reached for comment as an international expert to interpret the SeLECT 2.0 model for the broader medical community. **Safety Impact**. My commentary helps interpret the driving safety thresholds, which demonstrates the real-world societal impact of my scholarship. **Scientific Vision.** I offered advocacy for bioinformatics and biofluid biomarkers, aligning which aligns with my emphasis on "Precision Medicine."

2024 **Epilepsy and Neurodegenerative Disorders: The Relationship Between Stroke and Seizures – Webinar**. https://www.youtube.com/watch?v=UwY4qsvnWAE This webinar, *hosted by CURE* Epilepsy and presented by Dr Nishant Mishra, focuses on the critical relationship between stroke and seizures.

2023 **Poststroke seizures increase risk for mortality and poor outcomes.** https://www.springermedicine.com/cerebral-ischemia/non-epileptic-seizure/poststroke-seizures-mortality-poor-outcome/26102894

2011 **Patients with Diabetes and Prior Stroke Benefit from Thrombolytic Therapy for Treatment of Acute Stroke https://clinician.nejm.org/patients-diabetes-prior-stroke-benefit-thrombolytic-therapy-treatment-acute-stroke-EM201111180000001**

Bibliography:

Peer-Reviewed Original Research (A few select examples of the impact on guidelines and policy reported (extensive details available on request)

1. Hastak SM, Gorawara PS, **Mishra NK** . Abulia: no will, no way. Journal Of Association Of Physicians Of India 2005, 53: 814-8. PMID: 16334629 .
2. **Mishra NK** , Patel H, Hastak SM. Comprehensive stroke care: an overview. Journal Of Association Of Physicians Of India 2006, 54: 36-41. PMID: 16649738 .
3. Dalal PM, **Mishra NK** , Bhattacharjee M, Bhat P. Antithrombotic agents in cerebral ischaemia. The Journal Of The Association Of Physicians Of India 2006, 54: 555-61. PMID: 17089906 .
4. **Mishra NK** , Cereda C, Carota A. Lifetime Basilar Migraine: A Pontine Syndrome? Headache The Journal Of Head And Face Pain 2007, 48: 476-478. PMID: 18081824 , DOI: 10.1111/j.1526-4610.2007.01001.x .
5. Carota A, **Mishra N** , Allaoua M, Ghika J. A Squint of Brain: A Capgras Syndrome Variant. Journal Of Neuropsychiatry 2008, 20: 109-110. PMID: 18305297 , DOI: 10.1176/jnp.2008.20.1.109 .
6. **Mishra NK** , Hastak S. Poststroke Hallucination Delusion Syndrome. Journal Of Neuropsychiatry 2008, 20: 116-116. PMID: 18305304 , DOI: 10.1176/jnp.2008.20.1.116 .

7. **Mishra NK** , Rossetti AO, Ménétrey A, Carota A. Recurrent Wernicke's Aphasia: Migraine and Not Stroke! Headache The Journal Of Head And Face Pain 2009, 49: 765-768. PMID: 19456883 , DOI: 10.1111/j.1526-4610.2008.01255.x .
8. **Mishra NK** , Albers GW, Davis SM, Donnan GA, Furlan AJ, Hacke W, Lees KR. Mismatch-Based Delayed Thrombolysis. Stroke 2009, 41: e25-e33. PMID: 19926836 , DOI: 10.1161/strokeaha.109.566869 .

Significance:
Items 1–8: Clinical Foundation and the Transition to Global Research Leadership (2005–2009)
This early body of work documents my trajectory from a focused clinical neurologist to a leader in international stroke research. My early publications (Items 1, 4-7) in Headache and the Journal of Neuropsychiatry demonstrate a refined skill in complex neurodiagnostic reasoning, particularly at the intersection of vascular and behavioural neurology.

This clinical foundation culminated in the landmark publication, 'Mismatch-Based Delayed Thrombolysis' (Item 8) in Stroke. Published in 2009, this collaborative work with the world's leading stroke investigators helped shift the paradigm of acute stroke treatment toward imaging-based selection. Collectively, these eight papers establish that my current leadership of global repositories (IPSERR) and consortia (IPSERC) is built upon a 20-year foundation of clinical excellence and high-level international collaboration.

9. **Mishra NK** , Khadilkar SV. **Stroke program for India**. Annals Of Indian Academy Of Neurology 2010, 13: 28-32. PMID: 20436743 , PMCID: PMC2859584 , DOI: 10.4103/0972-2327.61273 .

Significance: *In this foundational work, I proposed a transformative national stroke care model for India, a country facing a silent epidemic with a severe shortage of specialists. By advocating for the creation of 'Strokology' and a multi-disciplinary training framework, this paper provided the conceptual architecture for a national 'Fight-Stroke' program. This work has been instrumental in shifting the focus from specialized hospital-based care to a scalable public health approach, directly influencing how stroke care is organized in low- and middle-income countries (LMICs).*

10. **Mishra NK** , Davis SM, Kaste M, Lees KR. Comparison of Outcomes Following Thrombolytic Therapy Among Patients With Prior Stroke and Diabetes in the Virtual International Stroke Trials Archive (VISTA). Diabetes Care 2010, 33: 2531-2537. PMID: 20843977 , PMCID: PMC2992183 , DOI: 10.2337/dc10-1125 .

Impact: Challenging Exclusion Criteria*: Before this study, patients with both diabetes and a prior stroke were often excluded from receiving intravenous thrombolysis (IVT) due to fears of increased bleeding risks, a restriction specifically written into European licensing for alteplase.* ***Evidence for Safety and Efficacy****: By analyzing the Virtual International Stroke Trials Archive (VISTA), the authors demonstrated that these patients actually had better functional outcomes when treated with thrombolysis compared to those who were not, with no significant increase in symptomatic intracranial hemorrhage.* ***AHA/ASA Guideline Influence****: The study contributed to the American Heart Association/American Stroke Association (AHA/ASA) guidelines, which shifted toward supporting IVT for these patients, noting that withholding treatment was not justified by the data.* ***International Policy Shifts****: It highlighted the discrepancy between U.S. and European policies, serving as a key piece of evidence for experts calling to harmonize global standards and remove "prior stroke and diabetes" as an absolute contraindication*

11. **Mishra NK** , Lyden P, Grotta JC, Lees KR. Thrombolysis Is Associated With Consistent Functional Improvement Across Baseline Stroke Severity. Stroke 2010, 41: 2612-2617. PMID: 20947852 , DOI: 10.1161/strokeaha.110.589317 .

Impact: *Referenced in two clinical guidelines: Thrombus composition and thrombolysis resistance in stroke; Research and Practice in Thrombosis and Haemostasis (2023) and Guidelines for the Intravenous Application of Recombinant Tissue-type Plasminogen Activator (Alteplase), the Second Edition, October 2012: A Guideline From the Japan Stroke Society (2013)*

12. **Mishra NK** , Diener HC, Lyden PD, Bluhmki E, Lees KR. Influence of Age on Outcome From Thrombolysis in Acute Stroke. Stroke 2010, 41: 2840-2848. PMID: 21030710 , DOI: 10.1161/strokeaha.110.586206 .

13. **Mishra NK** , Ahmed N, Andersen G, Egido JA, Lindsberg PJ, Ringleb PA, Wahlgren NG, Lees KR. Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive. The BMJ 2010, 341: c6046. PMID: 21098614 , PMCID: PMC2990864 , DOI: 10.1136/bmj.c6046 .

Impact: *Referenced in 1 policy sources and in 5 clinical guideline sources: The Chinese Stroke Association scientific statement: intravenous thrombolysis in acute ischaemic stroke (2017); AHA/ASA Guidelines for the Early Management of Patients With Acute Ischemic Stroke (2013); Guía para el tratamiento del infarto cerebral agudo (2011); Guidelines for the Intravenous Application of Recombinant Tissue-type Plasminogen Activator (Alteplase), the Second Edition, October 2012: A Guideline From the Japan Stroke Society (2013); Postępowanie w udarze mózgu – wytyczne Grupy Ekspertów Sekcji Chorób Naczyniowych Polskiego Towarzystwa Neurologicznego. Aktualizacja 2013: leczenie trombolityczne (2013).*

Items 12 & 13: Redefining Stroke Treatment for the Aging Population
"In 2010, I led two landmark studies published in The BMJ and Stroke that significantly changed the global standard of care for elderly stroke patients. By conducting a controlled comparison of the world's largest stroke registries (SITS and VISTA), I provided the first definitive evidence that thrombolysis is both safe and effective in patients over the age of 80. This work addressed a major health disparity and led to the revision of international clinical guidelines to include the very elderly. These publications not only established my early leadership in geriatric vascular neurology but also demonstrated my foundational expertise in managing and analyzing massive international clinical datasets—a skill set that remains the backbone of my current research program.

14. Lees K, **Mishra N** . Authors' reply. The BMJ 2011, 342: d312. DOI: 10.1136/bmj.d312 .
15. **Mishra NK** , Shuaib A, Lyden P, Diener HC, Grotta J, Davis S, Davalos A, Ashwood T, Wasiewski W, Lees KR. Home Time Is Extended in Patients With Ischemic Stroke Who Receive Thrombolytic Therapy. Stroke 2011, 42: 1046-1050. PMID: 21350199 , DOI: 10.1161/strokeaha.110.601302 .

16. Lees JS, **Mishra NK** , Saini M, Lyden PD, Shuaib A. Low Body Temperature Does Not Compromise the Treatment Effect of Alteplase. Stroke 2011, 42: 2618-2621. PMID: 21757664 , DOI: 10.1161/strokeaha.110.611210 .

Impact: Referenced in one policy document -- https://www.gov.uk/government/publications/alteplase-for-treatment-of-acute-ischaemic-stroke-independent-review

17. **Mishra NK** , Russmann H, Granziera C, Maeder P, Annoni JM. Mutism and Amnesia following High-Voltage Electrical Injury: Psychogenic Symptomatology Triggered by Organic Dysfunction? European Neurology 2011, 66: 229-234. PMID: 21952143 , DOI: 10.1159/000330953 .

18. **Mishra NK** , Ahmed N, Davalos A, Iversen HK, Melo T, Soinne L, Wahlgren N, Lees KR. Thrombolysis outcomes in acute ischemic stroke patients with prior stroke and diabetes mellitus. Neurology 2011, 77: 1866-1872. PMID: 22094479 , DOI: 10.1212/wnl.0b013e318238ee42 .

19.

Impact: Referenced in one policy document -- https://www.gov.uk/government/publications/alteplase-for-treatment-of-acute-ischaemic-stroke-independent-review and recommended on https://archive.connect.h1.co/article/13406958/

20. Morgan TC, Dawson J, Spengler D, Lees KR, Aldrich C, **Mishra NK** , Lane K, Quinn TJ, Diener-West M, Weir CJ, Higgins P, Rafferty M, Kinsley K, Ziai W, Awad I, Walters MR, Hanley D. The Modified Graeb Score. Stroke 2013, 44: 635-641. PMID: 23370203 , PMCID: PMC6800016 , DOI: 10.1161/strokeaha.112.670653 .
Impact: Referenced in Recommendations From the International Stroke Genetics Consortium, Part 1 (2014).

21. Frank B, Grotta JC, Alexandrov AV, Bluhmki E, Lyden P, Meretoja A, **Mishra NK** , Shuaib A, Wahlgren NG, Weimar C, Lees KR. Thrombolysis in Stroke Despite Contraindications or Warnings? Stroke 2013, 44: 727-733. PMID: 23391774 , DOI: 10.1161/strokeaha.112.674622 .

Impact: *A comprehensive analysis of the VISTA that examined whether several iv rtPA exclusions made sense, work that was used in several stroke policy and guidelines statements to advise practitioners about thrombolytic therapy, e.g. The Chinese Stroke Association scientific statement: intravenous thrombolysis in acute ischaemic stroke (2017); policy documents: https://www.gov.uk/government/publications/alteplase-for-treatment-of-acute-ischaemic-stroke-independent-review and https://www.gov.uk/government/publications/alteplase-for-treatment-of-acute-ischaemic-stroke-independent-review*

22. **Mishra NK** , Chan BP, Teoh H, Meng C, Lees KR, Chen C, Sharma VK. Postthrombolysis Outcomes in Acute Ischemic Stroke Patients of Asian Race-Ethnicity. International Journal Of Stroke 2013, 8: 95-99. PMID: 23490069 , DOI: 10.1111/ijs.12012 .

23. **Mishra NK** , Mandava P, Chen C, Grotta J, Lees KR, Kent TA. Influence of Racial Differences on Outcomes after Thrombolytic Therapy in Acute Ischemic Stroke. International Journal Of Stroke 2013, 9: 613-617. PMID: 24148895 , DOI: 10.1111/ijs.12162 .

24. Liggins JT, Yoo AJ, **Mishra NK** , Wheeler HM, Straka M, Leslie-Mazwi T, Chaudhry ZA, Kemp S, Mlynash M, Bammer R, Albers GW, Lansberg MG. A Score Based on Age and DWI Volume Predicts Poor Outcome following Endovascular Treatment for Acute Ischemic Stroke. International Journal Of Stroke 2013, 10: 705-709. PMID: 24207136 , PMCID: PMC4048330 , DOI: 10.1111/ijs.12207 .

25. **Mishra NK** , Albers GW, Christensen S, Marks M, Hamilton S, Straka M, Liggins JT, Kemp S, Mlynash M, Bammer R, Lansberg MG. Comparison of Magnetic Resonance Imaging Mismatch Criteria to Select Patients for Endovascular Stroke Therapy. Stroke 2014, 45: 1369-1374. PMID: 24699054 , PMCID: PMC4007191 , DOI: 10.1161/strokeaha.114.004772 .

26. **Mishra NK** , Christensen S, Wouters A, Campbell BC, Straka M, Mlynash M, Kemp S, Cereda CW, Bammer R, Marks MP, Albers GW, Lansberg MG. Reperfusion of Very Low Cerebral Blood Volume Lesion Predicts Parenchymal

Hematoma After Endovascular Therapy. Stroke 2015, 46: 46:1245-1249. PMID: 25828235 , PMCID: PMC4414872 , DOI: 10.1161/strokeaha.114.008171 .

27. Lansberg MG, Cereda CW, Mlynash M, **Mishra NK** , Inoue M, Kemp S, Christensen S, Straka M, Zaharchuk G, Marks MP, Bammer R, Albers GW, Saver J, Fayad P, Howard G, Tomsick. T, Jovin T, Wechsler L, DeCesare S, Thai D, Sherr A, Wilder M, Tricot A, Lutsep H, McDaneld L, Larsen D, Czartoski T, Keogh B, Malik A, Brown A, Bernstein R, Muskovich K, Chang C, Stern T, Warach S, Davis L, Fazekas F, Seifert-Held T. Response to endovascular reperfusion is not time-dependent in patients with salvageable tissue. Neurology 2015, 85: 708-714. PMID: 26224727 , PMCID: PMC4553034 , DOI: 10.1212/wnl.0000000000001853 .

Impact: Referenced in Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke (2018).

28. McGovern A, Pendlebury ST, **Mishra NK** , Fan Y, Quinn TJ. Test Accuracy of Informant-Based Cognitive Screening Tests for Diagnosis of Dementia and Multidomain Cognitive Impairment in Stroke. Stroke 2015, 47: 329-335. PMID: 26683423 , DOI: 10.1161/strokeaha.115.011218 .

Impact: cited in Russian guidelines: https://www.mediasphera.ru/issues/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova/2025/3-3/1199772982025033007

29. Jusufovic M, **Mishra NK** , Lansberg MG, Bath PM, Berge E, Sandset EC. Blood Pressure Management in Acute Stroke. Current Hypertension Reviews 2016, 12: 121-6. PMID: 26931471 , DOI: 10.2174/1573402112666160302102711 .

30. Cereda CW, Christensen S, Campbell B, **Mishra NK** , Mlynash M, Levi C, Straka M, Wintermark M, Bammer R, Albers GW, Parsons MW, Lansberg MG. A benchmarking tool to evaluate computer tomography perfusion infarct core predictions against a DWI standard. Journal Of Cerebral Blood Flow And Metabolism : Official Journal Of The International Society Of Cerebral Blood Flow And Metabolism 2016, 36: 1780-1789. PMID: 26661203 , PMCID: PMC5076783 , DOI: 10.1177/0271678x15610586 .

31. Federau C, Christensen S, Mlynash M, Tsai J, Kim S, Zaharchuk G, Inoue M, Straka M, **Mishra NK** , Kemp S, Lansberg MG, Albers GW. Comparison of stroke volume evolution on diffusion-weighted imaging and fluid-attenuated inversion recovery following endovascular thrombectomy. International Journal Of Stroke 2016, 12: 510-518. PMID: 27811306 , DOI: 10.1177/1747493016677985 .

32. Kasasbeh AS, Christensen S, Straka M, **Mishra N** , Mlynash M, Bammer R, Albers GW, Lansberg MG. Optimal Computed Tomographic Perfusion Scan Duration for Assessment of Acute Stroke Lesion Volumes. Stroke 2016, 47: 2966-2971. PMID: 27895299 , PMCID: PMC5134896 , DOI: 10.1161/strokeaha.116.014177 .

33. Beydoun HA, Beydoun MA, **Mishra NK** , Rostant OS, Zonderman AB, Eid SM. Comorbid Parkinson's disease, falls and fractures in the 2010 National Emergency Department Sample. Parkinsonism & Related Disorders 2016, 35: 30-35. PMID: 27887896 , PMCID: PMC5663222 , DOI: 10.1016/j.parkreldis.2016.11.005 .

34. Lansberg MG, Christensen S, Kemp S, Mlynash M, **Mishra N** , Federau C, Tsai JP, Kim S, Nogueria RG, Jovin T, Devlin TG, Akhtar N, Yavagal DR, Haussen D, Dehkharghani S, Bammer R, Straka M, Zaharchuk G, Marks MP, Albers GW, Investigators F. Computed tomographic perfusion to Predict Response to Recanalization in ischemic stroke. Annals Of Neurology 2017, 81: 849-856. PMID: 28486789 , PMCID: PMC5521988 , DOI: 10.1002/ana.24953 .

35. Tsai JP, Mlynash M, Christensen S, Kemp S, Kim S, **Mishra NK** , Federau C, Nogueira RG, Jovin TG, Devlin TG, Akhtar N, Yavagal DR, Bammer R, Straka M, Zaharchuk G, Marks MP, Albers GW, Lansberg MG. Time From Imaging to Endovascular Reperfusion Predicts Outcome in Acute Stroke. Stroke 2018, 49: 952-957. PMID: 29581341 , PMCID: PMC5875452 , DOI:10.1161/strokeaha.117.018858 .

36. Zusterzeel R, **Mishra NK** , Beydoun H, Laschinger J, Wu C, Dong LM, Lin JA, Marinac-Dabic D, Strauss DG, Caños DA. Sex-Specific Outcomes After Transcatheter Aortic Valve Replacement: FDA Patient-Level Meta-Analysis of Premarket Clinical Trials. Journal Of Women's Health 2018, 27: 808-814. PMID: 29741978 , DOI: 10.1089/jwh.2017.6760 .

37. **Mishra NK** , Campbell BCV. Editorial: Reperfusion Therapy for Acute Ischemic Stroke. Frontiers In Neurology 2019, 10: 1139. PMID: 31736855 , PMCID: PMC6828965 , DOI: 10.3389/fneur.2019.01139 .

38. Mishra NK, Leigh R and Campbell BCV (2021) Editorial: Intracranial Bleeding After Reperfusion Therapy in Acute Ischemic Stroke. Front. Neurol. 12:745993. doi: 10.3389/fneur.2021.745993
39. **Mishra N** , Liebeskind D. Artificial Intelligence in Stroke. 2021, 1-19. DOI: 10.1007/978-3-030-58080-3_197-1 .

40. **Mishra NK** , Leigh R, Campbell BCV. Editorial: Intracranial Bleeding After Reperfusion Therapy in Acute Ischemic Stroke. Frontiers In Neurology 2021, 12: 745993. PMID: 34531820 , PMCID: PMC8438163 , DOI: 10.3389/fneur.2021.745993 .

41. **Mishra NK** , Engel J, Liebeskind DS, Sharma VK, Hirsch LJ, Kasner SE, French JA, Devinsky O, Friedman A, Dawson J, Quinn TJ, Selim M, de Havenon A, Yasuda CL, Cendes F, Benninger F, Zaveri HP, Burneo JG, Srivastava P, Singh M, Bhatia R, Vishnu VY, Bentes C, Ferro J, Weiss S, Sivaraju A, Kim JA, Galovic M, Gilmore EJ, Pitkänen A, Davis K, Sansing LH, Sheth KN, Paz JT, Singh A, Sheth S, Worrall BB, Grotta JC, Casillas-Espinos PM, Chen Z, Nicolo JP, Yan B, Kwan P, Consortium F. International Post Stroke Epilepsy Research Consortium (IPSERC): A consortium to accelerate discoveries in preventing epileptogenesis after stroke. Epilepsy & Behavior 2021, 127: 108502. PMID: 34968775 , DOI: 10.1016/j.yebeh.2021.108502 .

    Impact: ***founding member/lead investigator****. In this landmark publication, I established* ***IPSERC****, the first international consortium dedicated to preventing post-stroke epilepsy. This work addresses a major barrier in the field—insufficient sample sizes at individual centres—by unifying global datasets.*

42. Platelet FcγRIIa Expression in Ischemic Stroke: A Marker of Increased Platelet Reactivity. J Schneider, Tristan Honda, Edward Feldmann, Adam de Havenon, Jose G Romano, Raul G Nogueira, Shyam Prabhakaran, Nishant K Mishra, Charles B Beaman, Jason Hinman, Christopher S Commichau, Peter Callas, Naoki Kaneko, Jose M Morales, Smit D Patel, Latisha K Sharma, Song Julia Kim, Heidi S Taatjes-Sommer, David S Liebeskind (2022) Stroke: Vascular and Interventional Neurology. 2022; https://doi.org/10.1161/SVIN.121.000201

43. **Mishra N** , Liebeskind D. Artificial Intelligence in Stroke. 2022, 1733-1751. DOI: 10.1007/978-3-030-64573-1_197 .

44. Schneider D, Honda T, Feldmann E, de Havenon A, Romano J, Nogueira R, Prabhakaran S, **Mishra N** , Beaman C, Hinman J, Commichau C, Callas P, Kaneko N, Morales J, Patel S, Sharma L, Kim S, Taatjes-Sommer H, Liebeskind D. Platelet FcγRIIa Expression in Ischemic Stroke: A Marker of Increased Platelet Reactivity. Stroke Vascular And Interventional Neurology 2022, 2: e000201. PMID: 41583630 , PMCID: PMC12778771 , DOI: 10.1161/svin.121.000201 .

45. Fakhra S, Sattar Y, Patel N, Aziz S, Titus A, Almas T, Aamir M, Sulaiman S, **Mishra N** , Elgendy I, Raina S, Jagadeesan V, Daggubati R, Alraies M. Comparison of Sex-Based In-Hospital Procedural Outcomes and Hospital Readmission Frequency After Patent Foramen Ovale Occluder Device Placement: A Propensity Matched National Cohort. Current Problems In Cardiology 2023, 48: 101662. PMID: 36868331 , DOI: 10.1016/j.cpcardiol.2023.101662 .

46. Misra S, Quinn T, Falcone G, Sharma V, de Havenon A, Zhao Y, Eldem E, French J, Yasuda C, Dawson J, Liebeskind D, Kwan P, **Mishra N** . Impact of genetic polymorphisms on the risk of epilepsy amongst patients with acute brain injury: A systematic review. European Journal Of Neurology 2023, 30: 1791-1800. PMID: 36912749 , DOI: 10.1111/ene.15777 .

47. Misra S, Khan E, Lam T, Mazumder R, Eldem E, Gururangan K, Hickman L, Goswami V, Funaro M, Montaner J, Quinn T, Liebeskind D, **Mishra N** . Biomarkers as prognostic determinants of epilepsy after post-acute central nervous system insults: a systematic review and meta-analysis (P3-5.017). Neurology 2023, 100 DOI: 10.1212/wnl.0000000000203165 .

48. Misra S, Vazquez J, Eldem E, Silva L, Mohidat S, Hickman L, Khan E, Funaro M, Yasuda C, Liebeskind D, Kasner S, **Mishra N** . Mortality and functional outcomes in patients with post-stroke epileptic seizures: a systematic review and meta-analysis (S45.006). Neurology 2023, 100 DOI: 10.1212/wnl.0000000000203419 .

49. Eldem E, Misra S, Quinn T, Driskell L, Perez A, Carrion C, Constable T, Schindler J, Zhao Y, Sico J, Hinman J, Allore H, Kiran S, Abutalebi J, Annoni J, **Mishra N** . Impact of Bilingualism on the Cognitive Outcomes in Stroke Survivors: A Systematic Review (P4-12.005). Neurology 2023, 100 DOI: 10.1212/wnl.0000000000203584 .

50. Misra S, Kasner S, Dawson J, Tanaka T, Zhao Y, Zaveri H, Eldem E, Vazquez J, Silva L, Mohidat S, Hickman L, Khan E, Funaro M, Nicolo J, Mazumder R, Yasuda C, Sunnerhagen K, Ihara M, Ross J, Liebeskind D, Kwan P, Quinn T, Engel J, **Mishra N** . Outcomes in Patients With Poststroke Seizures. JAMA Neurology 2023, 80: 1155-1165. PMID: 37721736 , PMCID: PMC10507596 , DOI: 10.1001/jamaneurol.2023.3240 .

Significance: *This landmark JAMA Neurology study is the definitive analysis of how post-stroke seizures impact recovery, mortality, and quality of life. It provides crucial data showing seizures are a major driver of poor outcomes, shifting clinical perspectives. As the senior author, I led an international team comprising the "who's who" of stroke and epileptology to produce this influential work, which is now used by clinicians to better counsel families and prioritise resources. Coordinating top global experts, I demonstrated leadership in complex, large-scale stroke and epilepsy research. This publication, part of my progression toward full professorship, marks a key milestone in my career, establishing me as a principal driver of influential studies in the field.*

51. **Mishra N** , Kwan P, Tanaka T, Sunnerhagen K, Dawson J, Zhao Y, Misra S, Wang S, Sharma V, Mazumder R, Funaro M, Ihara M, Nicolo J, Liebeskind D, Yasuda C, Cendes F, Quinn T, Ge Z, Scalzo F, Zelano J, Kasner S, Consortium I, Mishra N, Kwan P, Friedman A, Engel J. Clinical characteristics and outcomes of patients with post-stroke epilepsy: protocol for an individual patient data meta-analysis from the International Post-stroke Epilepsy Research Repository (IPSERR). BMJ Open 2023, 13: e078684. PMID: 37968000 , PMCID: PMC10660442 , DOI: 10.1136/bmjopen-2023-078684 .

Significance: *As Senior Author, I led the development and publication of this global research protocol, which serves as the foundation for the International Post-stroke Epilepsy Research Repository (IPSERR). This work establishes the methodological framework for a large-scale Individual Patient Data (IPD) meta-analysis, unifying disparate datasets from around the world. This paper is significant because it provides the standardised 'rules' for global collaboration in post-stroke epilepsy research, ensuring data harmony and statistical power that no single institution could achieve alone. This initiative has contributed to high-impact secondary publications and established me as a leader in Open Science and international research infrastructure.*

52. Misra S, Khan E, Lam T, Mazumder R, Gururangan K, Hickman L, Goswami V, Funaro M, Eldem E, Sansing L, Sico J, Quinn T, Liebeskind D, Montaner J, Kwan P, **Mishra N** . Common Pathways of Epileptogenesis in Patients With Epilepsy Post–Brain Injury. Neurology 2023, 101: e2243-e2256. PMID: 37550071 , PMCID: PMC10727219 , DOI: 10.1212/wnl.0000000000207749 .

Significance: *As the Senior Author on this major study published in Neurology, I led an international investigation into the shared biological drivers of epilepsy following various forms of brain injury. This work is groundbreaking because it moves beyond single-disease silos, identifying universal pathways of epileptogenesis that are common to stroke, trauma, and hemorrhage. This publication reflects my established role as an independent research leader and my commitment to mentoring the next generation of neurologists, as several co-authors were trainees under my direct supervision.*

53. **Mishra N** . Implications for driving based on the risk of seizures after ischaemic stroke. Journal Of Neurology Neurosurgery & Psychiatry 2024, 95: 794-794. PMID: 38749673 , DOI: 10.1136/jnnp-2024-333772 .

Impact: Invited commentary/ editorial. This is a **sole-authored** piece. As an internationally recognised leader in the field, I provide independent, critical thought on complex clinical issues.

54. Tanaka T, Ihara M, Fukuma K, **Mishra N** , Koepp M, Guekht A, Ikeda A. Pathophysiology, Diagnosis, Prognosis, and Prevention of Poststroke Epilepsy. Neurology 2024, 102: e209450. PMID: 38759128 , PMCID: PMC11175639 , DOI: 10.1212/wnl.0000000000209450 .

Impact: Worked alongside global leaders from Japan (Ihara, Tanaka), the UK (Koepp), and Russia (Guekht; ILAE president), which reinforces my status as an internationally recognised authority. This paper serves as a “white paper”, a comprehensive review published in Neurology, that provides the authoritative framework for our current understanding of post-stroke epilepsy. I collaborated with a select group of international experts to synthesize the mechanistic drivers of epileptogenesis with practical diagnostic and prognostic criteria. This work is significant because it integrates complex basic science—such as the role of blood-brain barrier disruption and neuroinflammation—into a clinical roadmap for risk stratification. It has become a highly cited reference for both

researchers and clinicians, serving as a primary educational resource for the standard of care in the transition from acute stroke to chronic seizure management

55. Misra S, Kawamura Y, Singh P, Sengupta S, Nath M, Rahman Z, Kumar P, Kumar A, Aggarwal P, Srivastava A, Pandit A, Mohania D, Prasad K, **Mishra N** , Vibha D. Prognostic biomarkers of intracerebral hemorrhage identified using targeted proteomics and machine learning algorithms. PLOS ONE 2024, 19: e0296616. PMID: 38829877 , PMCID: PMC11146689 , DOI: 10.1371/journal.pone.0296616 .

56. Clocchiatti-Tuozzo S, Rivier C, Misra S, Zelano J, Mazumder R, Sansing L, de Havenon A, Hirsch L, Liebeskind D, Gilmore E, Sheth K, Kim J, Worrall B, Falcone G, **Mishra N** . Polygenic Risk of Epilepsy and Poststroke Epilepsy. Stroke 2024, 55: 2835-2843. PMID: 39502073 , PMCID: PMC11653790 , DOI: 10.1161/strokeaha.124.047459 .

Impact: Published in Stroke, the leading journal in the field, this study is a cornerstone of my research program in genomic precision medicine. As the Senior Author, I led a multi-institutional team to demonstrate that a patient's polygenic risk score can independently predict the development of post-stroke epilepsy. This work is of particular significance as it served as the primary preliminary data supporting our successfully funded VA project. We are now expanding this research using the Million Veteran Program (MVP) dataset to develop a genetic screening tool for veterans. This paper exemplifies my ability to translate complex genomic data into funded research initiatives that directly impact federal health policy and veteran care.

57. Misra S, Singh P, Sengupta S, Kushwaha M, Rahman Z, Bhalla D, Talwar P, Nath M, Chakraborty R, Kumar P, Kumar A, Aggarwal P, Srivastava A, Pandit A, Mohania D, Prasad K, **Mishra N** , Vibha D. Subtyping strokes using blood-based protein biomarkers: A high-throughput proteomics and machine learning approach. European Journal Of Clinical Investigation 2024, 55: e14372. PMID: 39655799 , DOI: 10.1111/eci.14372 .

58. Misra S, Wang S, Quinn T, Dawson J, Zelano J, Tanaka T, Grotta J, Khan E, Beriwal N, Funaro M, Perla S, Dev P, Larsson D, Hussain T, Liebeskind D, Yasuda C, Altalib H, Zaveri H, Elshahat A, Hitawala G, Wang E, Kitagawa R, Pathak A, Scalzo F, Ihara M, Sunnerhagen K, Walters M, Zhao Y, Jette N, Kasner S, Kwan P, **Mishra N** . Antiseizure Medications in Poststroke Seizures. Neurology 2025, 104: e210231. PMID: 39808752 , DOI: 10.1212/wnl.0000000000210231 .

Impact: *Published in Neurology, the leading clinical journal in the field, this paper represents a culmination of my leadership in post-stroke epilepsy research. As the senior author, I directed an international team of experts to synthesise the evidence on the efficacy and safety of antiseizure medication (ASM) specifically for stroke survivors. This work is critical because it goes beyond general epilepsy guidelines to provide tailored pharmacological recommendations for stroke. Since its publication, it has become a foundational reference for clinicians, addressing a key gap in neuro-critical care and long-term stroke recovery. My role involved all aspects of this project e.g., conceptualising the study, coordinating the international expert panel, mentoring the junior team members in conducting the analysis, and final manuscript integration, representing the primary intellectual oversight of the project.*

59. Misra S, **Mishra N** . Activated protein C: A potential therapeutic target of post-stroke epileptogenesis. Epilepsy & Behavior 2025, 164: 110233. PMID: 39826181 , DOI: 10.1016/j.yebeh.2024.110233 .

60. Beydoun H, Beydoun M, Weiss J, Brunner R, **Mishra N** , Ding M, Wactawski-Wende J, Gradidge P, Liu S, Tsai J. Cardiovascular disease, bone fracture, and all-cause mortality risks among postmenopausal women by arthritis and veteran status: A multistate Markov transition analysis. GeroScience 2025, 47: 4169-4186. PMID: 39875753 , PMCID: PMC12181562 , DOI: 10.1007/s11357-025-01527-7 .

61. Beydoun H, Beydoun M, Khatana S, Nixdorff N, **Mishra N** , Tsai J. Sex-specific associations between homelessness and cerebrovascular disease among aging US veterans in the Veterans Affairs healthcare system. GeroScience 2025, 47: 6985-6998. PMID: 40588576 , PMCID: PMC12638493 , DOI: 10.1007/s11357-025-01758-8 .

Impact: *This study represents a significant contribution to our understanding of the social determinants of cerebrovascular health. Utilizing the vast data resources of the Veterans Affairs (VA) healthcare system, I co-led an investigation into how homelessness independently elevates stroke risk among aging veterans. Crucially, we identified sex-specific disparities in these associations, providing a roadmap for more tailored social and medical interventions within the VA. This work underscores my commitment to health equity and demonstrates the power of using large-scale administrative data to identify and protect the most vulnerable segments of the aging population*

62. Schubert K, Zelano J, Seiffge D, Brigo F, Trinka E, **Mishra N** , Russo E, Galovic M. Safety and Effectiveness of Direct Oral Anticoagulants in Combination with Antiseizure Medications: Protocol for a Systematic Review and Meta-analysis. Neurology And Therapy 2025, 14: 2737-2750. PMID: 41039177 , PMCID: PMC12623587 , DOI: 10.1007/s40120-025-00836-5 .

63. Dalli L, Olaiya M, Yu A, Reeves M, Cadilhac D, Nedkoff L, Feigin V, Norrving B, Kapral M, Whiteley W, Schott A, Ferrari J, Christensen H, Mac Grory B, Smith E, Béjot Y, Vyas M, **Mishra N** , Park J, Hill M, Christensen C, Gall S, Kilkenny M. Harnessing Routinely Collected Health Data for Global Monitoring of Stroke: Roadmap and Vision for INSPIRE-STROKE. Neuroepidemiology 2025, 1-10. PMID: 41052256 , DOI: 10.1159/000548781 .

Impact: *This paper addresses the "data gap" in global health. It outlines how to move from fragmented local registries to a unified global system using Routinely Collected Health Data (RCHD) like electronic health records and administrative claims. I am listed alongside world-renowned figures (e.g., Feigin, Norrving, Kapral), which demonstrates that I am part of the "inner circle" shaping global standards in neuroepidemiology.*

64. Kawamura Y, Trinka E, Quinn T, Emsley H, Zelano J, Tanaka T, Ihara M, Sansing L, Liebeskind D, **Mishra N** . Pharmacological strategies for preventing post-stroke seizures and epilepsy. Frontiers In Neurology 2026, 16: 1709077. PMID: 41586111 , PMCID: PMC12823330 , DOI: 10.3389/fneur.2025.1709077 .

Impact: *This is a "state-of-the-art" review that synthesises the current landscape of pharmacological interventions. This paper demonstrates my collaboration with international leaders in the field (Trinka, Liebeskind, etc.), signalling my standing within this elite global peer group.*

65. Wang EY, Misra S, Yan J, Chook PY, Kawamura Y, Kitagawa R, Kim JA, Gilmore EJ, de Havenon A, Sivaraju A, Hirsch LJ, Falcone GJ, Rangaraju S, Sansing LH, Magid-Bernstein J, **Mishra NK**. Characterizing inflammatory biomarkers in post-stroke seizure risk and outcome prognostication. PLOS One 2026, 21 DOI: 10.1371/journal.pone.0345752.

Books

1. Nishant K. Mishra. Use of thrombolytic therapy beyond current recommendations for acute ischaemic stroke; PhD Thesis; University of Glasgow, Scotland, UK
2. Lansberg MG, Mishra NK, Christensen S, Campbell B. Chapter: Perfusion profiles for favorable and unfavorable outcome. Book: MR & CT Perfusion Imaging: Clinical Applications and Theoretical Principles. Editor: Roland Bammer Publisher: Wolters Kluwer (2015)
3. Reperfusion therapy for acute ischaemic stroke. Frontiers in Neurology. 2020 Edited by Nishant K. Mishra, MD; Bruce Campbell, MD.
4. Mishra N.K., Liebeskind D.S. (2020) Artificial Intelligence in Stroke. In: Lidströmer N., Ashrafian H. (eds) Artificial Intelligence in Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-58080-3_197-1
5. Mishra, N. K., Leigh, R., Campbell, B., eds. (2021). Intracranial Bleeding After Reperfusion Therapy in Acute Ischemic Stroke. Lausanne: Frontiers Media SA. doi: 10.3389/978-2-88971-508-4
6. **Mishra N** , Misra S, Annoni J. Language in bilingual speakers with neurodegenerative disease. 2025, 349-368. DOI: 10.1093/oxfordhb/9780198888482.013.0020 . **(Book Chapter)**

Yale CV Part 2

Version Date: 4/20/2026

Name: Nishant Kumar Mishra, PhD, FRCP, FAHA, FESC, MBBS, MD

Current Position: Assistant Professor of Neurology, Department of Neurology

Section A: Narrative Descriptions

A1. Overview of Responsibilities and Contributions

My career has come full circle: after influencing global guidelines on acute stroke, I now lead an international consortium, IPSERC, to prevent post-stroke epilepsy. As an authority in cerebrovascular medicine, my work has shaped national and international stroke guidelines and policy(e.g., Demaerschalk et al., AHA 2016). At Yale, I lead a consortium and research group focused on post-stroke outcomes and neurological preservation. My expertise is validated by NIH reviewer roles and invitations to serve as a grant reviewer for UKRI and the Swiss National Science Foundation. Recognised as a thought leader, I authored an editorial on post-stroke seizure risk for JNNP, which reached a global audience via Medscape. My leadership includes service on the American Epilepsy Society Scientific Program, the YIGH Review Committees, and the VA Stroke Director. Combining two decades of clinical experience with scholarship, I support Yale's research and clinical goals while earning national and international recognition.

A2. Overview of Contributions to Well-being of Community

My commitment to community well-being rests on **two pillars:** delivering equitable, high-quality care to Veterans and Yale patients and expanding access to medical knowledge to enhance stroke recovery worldwide.
Humanistic Clinical Excellence: By maintaining a traditional neurology practice focused on listening and storytelling, I improve patient trust and adherence, serving as a compassionate care model recognised by peers.
Implementation of Standards: I have implemented advanced reperfusion and recovery protocols at the VA, delivering top general and vascular neurology care to Veterans.
Global Advocacy and Guideline Transformation (National/International Impact) My scholarly work advocates for the 'excluded' patient. For instance, my 2010 BMJ and Stroke study challenged the exclusion of age-based stroke treatment, and my work from 2008-2012 helped change the 2016 AHA/ASA Guidelines and contributed to international stroke policy.
Enhancing Cognitive Reserve through Cultural Diversity. My research into bilingualism and cognitive reserve aims to empower diverse communities by exploring how linguistic diversity protects the brain.

A3. Clinical Activities Narrative

Clinical Expertise, Leadership, and Responsibilities
As a Stroke Neurologist at the **West Haven VA Medical Centre** and a faculty member of the **Yale Vascular Neurology Program**, I carry a high-acuity clinical load. My responsibilities include managing complex stroke cases, overseeing the inpatient stroke service, and serving as a lead consultant for the VA Connecticut and the Yale Stroke Neurology program.

I lead a multidisciplinary team of fellows, residents, and nursing staff, ensuring that evidence-based optimal stroke care is applied at the bedside.

Clinical Reputation and Recognition

National/International: I came to the US in 2012 with an established international reputation in stroke medicine, particularly in acute stroke therapy. In 2011, the current Chair of Neurology, then a faculty member at the University of Pennsylvania, graciously attested to my growing reputation within the field. My work then contributed to national and international stroke care policy and guidelines. At Yale, I focused on interdisciplinary research. My reputation here is anchored by my role as the founder of **IPSERC**. I am a recognised authority in post-stroke epilepsy (PSE), frequently invited to speak at major conferences (e.g., the European Stroke Organisation Conference, the American Epilepsy Society Meeting, IANCON, and STESS/ILAE) and to serve on expert panels (e.g., Guidelines co-chair, ESO).

Health System/State: Within the Yale and VA systems, I am recognised for my clinical acumen and wisdom. My receipt of **institutional 'Kudos' at the VA** — driven by peer and student feedback — and patients' appreciation for my wisdom formally validate my reputation for excellence and humanism in a high-stakes clinical environment.

Development, Administration, and Quality Improvement (QI)

Program Leadership: I have been instrumental in administering the VA Stroke Program, ensuring our facility maintains its status as a high-performing stroke centre.

Quality Care Measures: I led initiatives to streamline **"door-to-decision"** times for acute stroke patients. By applying my research findings on rtPA exclusions (from the **BMJ 2010** data), we expanded the treatment pool to include the very elderly and those with complex comorbidities, directly improving the facility's reperfusion rates.

Influence on Clinical Practice and Innovation

Global Influence: My work on **rtPA exclusion criteria** (cited in the **2016 AHA Guidelines and several national and international stroke** policies) and my **2023 JAMA Neurology** meta-analysis on PSE have shifted the global standard of care. I have transformed how clinicians perceive the risks of thrombolysis and how they monitor for post-stroke mortality.

Dissemination: Beyond my 2,988 citations, I actively disseminate expertise through the **Yale Vascular Neurology Program** lectures and by drafting guidelines to standardise the management of post-stroke seizures.

Diversity, Equity, Inclusion, and Wellbeing (DEI)

The Bilingualism Initiative: My research into **cognitive reserve and bilingualism** is a direct contribution to health equity. It highlights the neurological "assets" of diverse, multi-lingual communities, moving away from a deficit-based model of stroke recovery.

Veteran Advocacy: By serving at the West Haven VA, I focus my clinical energy on an underserved and ageing population, ensuring that the highest tier of Yale-level academic medicine is accessible to those who served.

Impact on the Field and Organisational Culture

Organisational Culture: I strengthen Yale's mission by bridging the gap between **Neurology and Neurosurgery** (via epilepsy research) and between **Basic Science and Clinical Care** . My "traditional" approach—sharing stories and clinical pearls—preserves the mentor-apprentice culture that is foundational to Yale Medicine.

Field Impact: I have moved the field of stroke from a narrow focus on "survival" to a holistic focus on "brain stewardship," encompassing epilepsy prevention, genomic risk, and cognitive preservation.

A4. Educational Activities Narrative

Clinical Excellence and System Leadership

Clinical Reputation and Responsibilities:

I serve as a cornerstone of the neurovascular service at the **West Haven VA Medical Center** , managing a high-volume practice that consistently surpasses institutional benchmarks for access and productivity. As a 'master clinician,' my clinical judgment is the standard for complex neurovascular consultations across the regional VA network.

Influence on Practice:
As leader of the **International Post Stroke Epilepsy Research Consortium (IPSERC),** I have redefined global standards for brain stewardship. By integrating my scholarly work into VA stroke protocols, I have directly updated regional standards of care to reflect the most current evidence-based practices in reperfusion and recovery.
Quality and Humanism:
My dedication to the 'art' of neurology is validated by **institutional 'Kudos' at the VA**, awarded for my ability to maintain meticulous, high-standard semiology while delivering humanistic, patient-centred care in high-stakes clinical scenarios.

Mentorship and Educational Global Pipeline
Diverse International Pipeline: In the **Yale Vascular Neurology Program**, I have cultivated a global mentorship pipeline that bridges the laboratory and the bedside. My successes range from guiding a **Yale MD student** to a prestigious **AAN Award** and a successful residency match to mentoring a visiting faculty member who currently holds the rank of **Professor in Gothenburg**.
National Faculty Development: My educational impact extends nationally through the mentorship of **NIH StrokeNet Fellows** at NYU and internationally with the **World Stroke Organisation**. I ensure that Yale's clinical rigour and ethical standards influence stroke care standards across diverse institutions.
Educational Philosophy: I utilise clinical storytelling to ground tech-savvy trainees in the fundamental skills of neurological examination and clinical history, fostering a professional identity that balances scientific precision with medical ethics

Community Well-Being and Institutional Citizenship Criterion:
Community Advocacy: My research into **bilingualism and cognitive reserve** directly supports health equity by highlighting cultural assets as mechanisms for neurological resilience in diverse communities. This work seeks to provide cost-effective, community-based methods for preventing post-stroke cognitive decline.
Veteran Health: Serving at the West Haven VA, I prioritise the well-being of a vulnerable and ageing community, ensuring they have access to innovative, peer-recognised expertise that defined the **2016 AHA Guideline.**

A5. Research/Scholarship Activities Narrative

Overview of Academic Contributions
With a career spanning two decades across leading institutions in India, Europe, and the United States, I have established a sustained record of research that has fundamentally altered the standard of care in stroke neurology.
My academic trajectory is marked by three distinct phases of impact: the refinement of thrombolytic protocols, the expansion of the reperfusion window through advanced imaging, and my current Yale-based mission to pioneer the field of post-stroke epileptogenesis and cognitive reserve.

Phase I: Redefining Global Standards for Reperfusion (2008–2014)
Early in my career, I challenged established dogmas regarding IV rtPA exclusion criteria. My research, published in premier journals including *BMJ*, *Neurology*, and *Stroke*, demonstrated that several traditional exclusions were medically unfounded.
Guideline Impact: This body of work gained significant media attention and was formally incorporated into the **2016 AHA/ASA Stroke Guideline updates** and several other countries' guidelines and stroke policies, directly expanding the pool of patients eligible for life-saving thrombolysis.
Imaging Innovation: Subsequently, my work on perfusion imaging helped provide the scientific scaffolding for clinical trials that expanded the therapeutic window for both tPA and endovascular thrombectomy, shifting the field toward a 'tissue-clock' rather than a 'time-clock' model.

Phase II: The Yale Era—Mechanisms of Epileptogenesis and Recovery
Upon joining the Yale faculty, I pivoted my research focus toward the most pressing unmet needs in stroke survivorship: post-stroke epilepsy and cognitive decline.
Epileptogenesis: I have emerged as an international thought leader in the mechanisms of post-stroke seizures. I am currently leading collaborative efforts to design clinical trials and secure extramural funding to develop the first generation of preventative therapeutics for this population.
Cognitive Reserve & Bilingualism: Investigating the neuro-protective effects of bilingualism, I have developed a research program exploring how linguistic diversity improves cognitive reserve. My pending **R01 submissions** aim to provide the first mechanistic data on how bilingualism delays post-stroke cognitive decline.
Rehabilitation Innovation: Given the data gaps in stroke recovery, I'm leading initiatives to improve post-stroke spasticity management, keeping Yale/VA at the forefront of comprehensive post-stroke care.

Section B: Supportive Data

B1. Percent Effort

Period: 2021-2022

Clinical

Activities with students/trainees present:	0%
Activities without students/trainees present:	78%

Education

Activities (not including clinical teaching as attending physician):	0%

Research

Research activities:	15%

Administrative

Administrative leadership:	7%

Delineate leadership role(s): Stroke director at the VA Connecticut. Co-convener IPSERC

Total (above categories should sum to 100%):	100%

Period: 2023-2026

Clinical

Activities with students/trainees present:	0%
Activities without students/trainees present:	50%

Education

Activities (not including clinical teaching as attending physician):	0%

Research

Research activities:	50%

Administrative

Administrative leadership:	0%

Delineate leadership role(s): Full-time at Yale.

Total (above categories should sum to 100%):	100%

B2. Data Clinical Activities

B3. Educational Activities Data

Mentoring

Name of trainee:	Shubham Misra
Position and period of mentorship:	Postdoc, 2022 - 2024
Research project:	Contributes to PI-initiated projects on post-stroke epilepsy, the role of bilingualism on stroke outcomes, and perfusion imaging-based patient selection for stroke therapies. Moved to Rengaraju lab to learn proteomics.
Publications:	(1) Abstract DP249: Integrative Bioinformatics Analysis to Identify Molecular Mechanisms and Biomarkers of Post-Stroke Epilepsy, (2) Language in bilingual speakers with neurodegenerative disease,(3) Activated protein C: A potential therapeutic target of post-stroke epileptogenesis, (4) Antiseizure Medications in Poststroke Seizures, Subtyping strokes using blood-based protein biomarkers: A high-throughput proteomics and machine learning approach, (5) Polygenic Risk of Epilepsy and Poststroke Epilepsy, (6) Prognostic biomarkers of intracerebral hemorrhage identified using targeted proteomics and machine learning algorithms, (7) Prognostication of Outcomes in Stroke Patients Using Inflammatory Biomarkers: Findings from the Yale Post-stroke Epilepsy Research Group (P3-5.010), (8) Common Pathways of Epileptogenesis in Patients With Epilepsy Post–Brain Injury, (9) Clinical characteristics and outcomes of patients with post-stroke epilepsy: protocol for an individual patient data meta-analysis from the International Post-stroke Epilepsy Research Repository (IPSERR), (10) Outcomes in Patients With Poststroke Seizures, Impact of Bilingualism on the Cognitive Outcomes in Stroke Survivors: A Systematic Review (P4-12.005), (11) Mortality and functional outcomes in patients with post-stroke epileptic seizures: a systematic review and meta-analysis (S45.006), (12) Biomarkers as prognostic determinants

	of epilepsy after post-acute central nervous system insults: a systematic review and meta-analysis (P3-5.017),(13) Impact of genetic polymorphisms on the risk of epilepsy amongst patients with acute brain injury: A systematic review, (14) Abstract TP229: Impact Of Genetic Polymorphisms On The Risk Of Epilepsy Amongst Patients With Acute Brain Injury: A Systematic Review
Current position:	Postdoc - Rengaraju Lab
Name of trainee:	Ethan Wang
Position and period of mentorship:	Ethan Wang, 2022 - 2026
Research project:	MD Thesis, To characterise the relationship between inflammatory markers and post-stroke epilepsy. Won the AAN Student Award 2024
Publications:	(1) Antiseizure Medications in Poststroke Seizures, Prognostication of Outcomes in Stroke Patients Using (2) Inflammatory Biomarkers: Findings from the Yale Post-stroke Epilepsy Research Group (P3-5.010)
Current position:	Resident elect - UPMC (Medicine)
Name of trainee:	Ece Eldem
Position and period of mentorship:	Postgrad associate, 2022 - 2023
Research project:	Role of bilingualism in improving cognitive reserve. Post Stroke Epilepsy Research
Publications:	(1) Common Pathways of Epileptogenesis in Patients With Epilepsy Post–Brain Injury, (2) Outcomes in Patients With Poststroke Seizures, Impact of Bilingualism on the Cognitive (3) Outcomes in Stroke Survivors: A Systematic Review (P4-12.005), (4) Mortality and functional outcomes in patients with post-stroke epileptic seizures: a systematic review and meta-analysis (S45.006), (5) Biomarkers as prognostic determinants of epilepsy after post-acute central nervous system insults: a systematic review and meta-analysis (P3-5.017), (6) Impact of genetic polymorphisms on the risk of epilepsy amongst patients with acute brain injury: A systematic review, (7) Abstract TP229: Impact Of Genetic Polymorphisms On The Risk Of Epilepsy Amongst Patients With Acute Brain Injury: A Systematic Review
Current position:	PhD Student at Universitätsmedizin Rostock, Translational Neurodegeneration Section
Name of trainee:	Erum I Khan
Position and period of mentorship:	Visiting Medical Student, 2022 - Present
Research project:	Erum I Khan joined my lab during her clinical rotations at Yale Neurology. She works in post-stroke epilepsy projects.
Publications:	(1) Antiseizure Medications in Poststroke Seizures, Common Pathways of Epileptogenesis in Patients With Epilepsy Post–Brain Injury, (2) Outcomes in Patients With Poststroke Seizures, (3) Mortality and functional outcomes in patients with post-stroke epileptic seizures: a systematic review and meta-analysis (S45.006), (4) Biomarkers as prognostic determinants of epilepsy after post-acute central nervous system insults: a systematic review and meta-analysis (P3-5.017)
Current position:	Neurology Resident, University of Alabama, Birmingham
Name of trainee:	Taimur Hussain
Position and period of mentorship:	Associate Research Scientist, 2022 - Present

Research project:	Stroke Research.
Publications:	(1) Antiseizure Medications in Poststroke Seizures
Current position:	Internal Medicine Resident, Detroit/ Fellow John Hopkins University
Name of trainee:	Pei Yi Chook
Position and period of mentorship:	Medical student, 2023
Research project:	Identifying factors that predict post-stroke seizures in patients with intracerebral haemorrhage: A retrospective cohort analysis
Publications:	(1) Prognostication of Outcomes in Stroke Patients Using Inflammatory Biomarkers: Findings from the Yale Post-stroke Epilepsy Research Group (P3-5.010)
Current position:	Medical Student, Malaysia
Name of trainee:	Yuki Kawamura
Position and period of mentorship:	Medical student, 2023 - Present
Research project:	Improving Post-stroke outcomes: 1. Post-stroke epilepsy 2. Biomarkers of post-stroke outcomes
Publications:	(1) Characterizing inflammatory biomarkers in post-stroke seizure risk and outcome prognostication., (2) Characterizing inflammatory biomarkers in post-stroke seizure risk and outcome prognostication, (3) Pharmacological strategies for preventing post-stroke seizures and epilepsy, (4) Prognostic biomarkers of intracerebral hemorrhage identified using targeted proteomics and machine learning algorithms
Current position:	Medical Student, Cambridge University; Visiting Student, Yale University
Name of trainee:	Johan Zelano
Position and period of mentorship:	Associate Research Scientist, 2023 - Present
Research project:	Visiting Scientist and Faculty member at Gothenberg University, Sweden
Publications:	(1) Pharmacological strategies for preventing post-stroke seizures and epilepsy, (2) Antiseizure Medications in Poststroke Seizures, (3) Polygenic Risk of Epilepsy and Poststroke Epilepsy
Current position:	Professor of Neurology, Gothenberg University, Sweden
Name of trainee:	Amr Ayman Abdelbary Elshahat
Position and period of mentorship:	Associate Research Scientist, 2024 - 2025
Research project:	Post stroke epilepsy research
Publications:	(1)Antiseizure Medications in Poststroke Seizures
Current position:	Yale trainee, transitioning to neurology residency in Texas this year
Name of trainee:	Matias Alet
Position and period of mentorship:	Faculty, 2024
Research project:	Neurologist in Argentina. Received mentorship on World Stroke Organisation pearls podcast noted below: **WSA Pearls Podcast: Diagnosis and Treatment of Post Stroke Epilepsy by Dr. Matías Alet**
Presentations:	WSA Pearls Podcast

Current position:	Associate Professor in Neurology at the Faculty of Medicine of the University of Buenos Aires
Name of trainee:	Sean Kelly
Position and period of mentorship:	Faculty, 2025
Research project:	**StrokeNET Fellow, March 2025. Topic:** "Longitudinal Investigation of Post-stroke Seizure Risk in Patients with Chronic Renal Disease"
Presentations:	StrokeNET Fellow Presentations, March 2025
Current position:	Faculty Stroke Neurologist, NYU
Name of trainee:	Monica Sarkar
Position and period of mentorship:	Postdoc, 2026 - Present
Research project:	**StrokeNET Fellow, March 2025** **Research Topic:** "Longitudinal Investigation of Post-stroke Seizure Risk in Patients with Chronic Renal Disease"
Presentations:	StrokeNET Fellow Presentation April 2026
Current position:	Fellow, University of Cincinnati

B4. Data scholarship/research activities

13. Misra S, Wang S, Quinn T, Dawson J, Zelano J, Tanaka T, Grotta J, Khan E, Beriwal N, Funaro M, Perla S, Dev P, Larsson D, Hussain T, Liebeskind D, Yasuda C, Altalib H, Zaveri H, Elshahat A, Hitawala G, Wang E, Kitagawa R, Pathak A, Scalzo F, Ihara M, Sunnerhagen K, Walters M, Zhao Y, Jette N, Kasner S, Kwan P, **Mishra N** . Antiseizure Medications in Poststroke Seizures. Neurology 2025, 104: e210231. PMID: 39808752 , DOI: 10.1212/wnl.0000000000210231 .
    Upon joining Yale, I pivoted my research to focus on post-stroke seizures (PSS). My leadership is shown by my 2025 lead-author publication in Neurology, a systematic review and meta-analysis of over 18,000 patients. This is the most comprehensive evaluation of antiseizure medications (ASMs) in post-stroke populations. We identified levetiracetam and lamotrigine as safe, while highlighting the risks of older agents such as phenytoin. This project involved a global network of experts from Glasgow, Karolinska, and Tokyo. It provides clinical outcome data—regarding adverse events and drug discontinuation—that were previously missing and are now guiding future clinical trials.

14. Clocchiatti-Tuozzo S, Rivier C, Misra S, Zelano J, Mazumder R, Sansing L, de Havenon A, Hirsch L, Liebeskind D, Gilmore E, Sheth K, Kim J, Worrall B, Falcone G, **Mishra N** . Polygenic Risk of Epilepsy and Poststroke Epilepsy. Stroke 2024, 55: 2835-2843. PMID: 39502073 , PMCID: PMC11653790 , DOI: 10.1161/strokeaha.124.047459 .
    Genomic Determinants of Stroke Recovery. My Yale research pioneered polygenic risk scores (PRS) for predicting neurological issues. In a 2024 Stroke study, I led a team that showed a genetic predisposition to epilepsy increases the risk of post-stroke epilepsy (PSE), particularly in cases of intracerebral haemorrhage. Key finding: a one-standard-deviation increase in the epilepsy PRS was associated with higher PSE risk, advancing personalised prognosis. This project highlights my leadership at Yale, uniting vascular neurology, neuro-critical care, and genomics experts to address recovery challenges **. This work led to the VA funding to investigate PRS in VA stroke patients.**

15. Misra S, Kasner S, Dawson J, Tanaka T, Zhao Y, Zaveri H, Eldem E, Vazquez J, Silva L, Mohidat S, Hickman L, Khan E, Funaro M, Nicolo J, Mazumder R, Yasuda C, Sunnerhagen K, Ihara M, Ross J, Liebeskind D, Kwan P, Quinn T, Engel J,

Mishra N . Outcomes in Patients With Poststroke Seizures. JAMA Neurology 2023, 80: 1155-1165. PMID: 37721736 , PMCID: PMC10507596 , DOI: 10.1001/jamaneurol.2023.3240 .
This paper provides key epidemiological evidence justifying future R01 applications and clinical trials. It is the definitive study establishing the global morbidity and mortality of post-stroke seizures (PSS). I led this landmark systematic review and meta-analysis published in JAMA Neurology, analyzing data from over 1.1 million patients to address the lack of standardised data on post-stroke outcomes. We demonstrated that PSS doubles mortality and worsens functional outcomes. Involving 24 collaborators across four continents, this work quantifies the 'mortality gap' in PSS, making it a primary reference and supporting efforts to develop preventive therapeutics and secure NIH R01 funding.

16. **Mishra NK** , Engel J, Liebeskind DS, Sharma VK, Hirsch LJ, Kasner SE, French JA, Devinsky O, Friedman A, Dawson J, Quinn TJ, Selim M, de Havenon A, Yasuda CL, Cendes F, Benninger F, Zaveri HP, Burneo JG, Srivastava P, Singh M, Bhatia R, Vishnu VY, Bentes C, Ferro J, Weiss S, Sivaraju A, Kim JA, Galovic M, Gilmore EJ, Pitkänen A, Davis K, Sansing LH, Sheth KN, Paz JT, Singh A, Sheth S, Worrall BB, Grotta JC, Casillas-Espinos PM, Chen Z, Nicolo JP, Yan B, Kwan P, Consortium F. International Post Stroke Epilepsy Research Consortium (IPSERC): A consortium to accelerate discoveries in preventing epileptogenesis after stroke. Epilepsy & Behavior 2021, 127: 108502. PMID: 34968775 , DOI: 10.1016/j.yebeh.2021.108502 .
This paper is the "Organisational Cornerstone" of my dossier, demonstrating my ability to convene global experts to address a major challenge. By founding and leading the International Post Stroke Epilepsy Research Consortium(IPSERC), I have progressed from a "productive researcher" to a "field-builder." Recognising the complexity of preventing PSE, IPSERC aims to create a global framework to harmonise PSE research across centres in the US, Europe, and India. IPSERC unites leaders from Yale, Harvard, the University of Pennsylvania, and other institutions to standardise phenotypes and accelerate the development of preventive therapies. I am actively shaping the infrastructure for next-generation stroke research.

17. **Mishra NK** , Ahmed N, Andersen G, Egido JA, Lindsberg PJ, Ringleb PA, Wahlgren NG, Lees KR. Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive. The BMJ 2010, 341: c6046. PMID: 21098614 , PMCID: PMC2990864 , DOI: 10.1136/bmj.c6046 .
My career has come full circle: I am now leading the international consortium that will define how we protect the brain during recovery (Neurology 2025, IPSERC). **Before coming to Yale, I informed the stroke community about how we treat acute stroke, having already changed the global guidelines**. In short, my multiple contributions, including this paper, from 2008 to 2012 informed stroke guidelines and policies in several countries. Examples include (1) The Chinese Stroke Association scientific statement: intravenous thrombolysis in acute ischaemic stroke (2017); AHA/ASA Guidelines for the Early Management of Patients With Acute Ischemic Stroke (2013); Guía para el tratamiento del infarto cerebral agudo (2011); Guidelines for the Intravenous Application of Recombinant Tissue-type Plasminogen Activator (Alteplase), the Second Edition, October 2012: A Guideline From the Japan Stroke Society (2013); Postępowanie w udarze mózgu – wytyczne Grupy Ekspertów Sekcji Chorób Naczyniowych Polskiego Towarzystwa Neurologicznego. Aktualizacja 2013: leczenie trombolityczne (2013), etc.